nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Obstructive airways disorder—Methotrexate—lymphatic system cancer	0.021	0.0218	CcSEcCtD
Solifenacin—Hyperkalaemia—Fludarabine—lymphatic system cancer	0.0158	0.0164	CcSEcCtD
Solifenacin—Intestinal obstruction—Vincristine—lymphatic system cancer	0.0144	0.015	CcSEcCtD
Solifenacin—Ileus—Vincristine—lymphatic system cancer	0.0139	0.0144	CcSEcCtD
Solifenacin—Depression—Mechlorethamine—lymphatic system cancer	0.0138	0.0144	CcSEcCtD
Solifenacin—Liver function test abnormal—Teniposide—lymphatic system cancer	0.0122	0.0127	CcSEcCtD
Solifenacin—CYP3A4—Cytarabine—lymphatic system cancer	0.012	0.318	CbGbCtD
Solifenacin—CYP3A4—Teniposide—lymphatic system cancer	0.0119	0.313	CbGbCtD
Solifenacin—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.0118	0.0122	CcSEcCtD
Solifenacin—Cystitis noninfective—Bleomycin—lymphatic system cancer	0.0115	0.012	CcSEcCtD
Solifenacin—Cystitis—Bleomycin—lymphatic system cancer	0.0114	0.0118	CcSEcCtD
Solifenacin—Drug interaction—Carmustine—lymphatic system cancer	0.0111	0.0115	CcSEcCtD
Solifenacin—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.0108	0.0112	CcSEcCtD
Solifenacin—Bladder pain—Bleomycin—lymphatic system cancer	0.0106	0.0111	CcSEcCtD
Solifenacin—Drug interaction—Vincristine—lymphatic system cancer	0.0106	0.011	CcSEcCtD
Solifenacin—Dysuria—Fludarabine—lymphatic system cancer	0.00942	0.00979	CcSEcCtD
Solifenacin—Hyperkalaemia—Mitoxantrone—lymphatic system cancer	0.00939	0.00976	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00916	0.00952	CcSEcCtD
Solifenacin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00885	0.00919	CcSEcCtD
Solifenacin—Renal failure—Fludarabine—lymphatic system cancer	0.00883	0.00918	CcSEcCtD
Solifenacin—Infection—Mechlorethamine—lymphatic system cancer	0.00879	0.00913	CcSEcCtD
Solifenacin—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00873	0.00908	CcSEcCtD
Solifenacin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00859	0.00893	CcSEcCtD
Solifenacin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00829	0.219	CbGbCtD
Solifenacin—Pharyngitis—Fludarabine—lymphatic system cancer	0.00801	0.00832	CcSEcCtD
Solifenacin—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00769	0.00799	CcSEcCtD
Solifenacin—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00763	0.00793	CcSEcCtD
Solifenacin—Malnutrition—Fludarabine—lymphatic system cancer	0.00702	0.0073	CcSEcCtD
Solifenacin—Liver disorder—Methotrexate—lymphatic system cancer	0.00699	0.00726	CcSEcCtD
Solifenacin—Hypertension—Teniposide—lymphatic system cancer	0.0069	0.00717	CcSEcCtD
Solifenacin—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00689	0.00716	CcSEcCtD
Solifenacin—Urinary retention—Vincristine—lymphatic system cancer	0.00677	0.00704	CcSEcCtD
Solifenacin—Muscular weakness—Carmustine—lymphatic system cancer	0.00658	0.00684	CcSEcCtD
Solifenacin—Confusional state—Teniposide—lymphatic system cancer	0.00658	0.00683	CcSEcCtD
Solifenacin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00652	0.00677	CcSEcCtD
Solifenacin—Infection—Teniposide—lymphatic system cancer	0.00648	0.00673	CcSEcCtD
Solifenacin—Tachycardia—Teniposide—lymphatic system cancer	0.00636	0.00661	CcSEcCtD
Solifenacin—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00634	0.00659	CcSEcCtD
Solifenacin—Muscular weakness—Vincristine—lymphatic system cancer	0.00628	0.00653	CcSEcCtD
Solifenacin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00626	0.0065	CcSEcCtD
Solifenacin—Cough—Fludarabine—lymphatic system cancer	0.00613	0.00637	CcSEcCtD
Solifenacin—Confusional state—Fludarabine—lymphatic system cancer	0.00578	0.00601	CcSEcCtD
Solifenacin—Dysuria—Vincristine—lymphatic system cancer	0.00576	0.00598	CcSEcCtD
Solifenacin—Depression—Carmustine—lymphatic system cancer	0.00573	0.00596	CcSEcCtD
Solifenacin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00573	0.00596	CcSEcCtD
Solifenacin—CYP3A4—Vincristine—lymphatic system cancer	0.0057	0.151	CbGbCtD
Solifenacin—Infection—Fludarabine—lymphatic system cancer	0.00569	0.00592	CcSEcCtD
Solifenacin—Decreased appetite—Teniposide—lymphatic system cancer	0.00567	0.00589	CcSEcCtD
Solifenacin—Renal failure—Carmustine—lymphatic system cancer	0.00565	0.00588	CcSEcCtD
Solifenacin—Vomiting—Mechlorethamine—lymphatic system cancer	0.00562	0.00585	CcSEcCtD
Solifenacin—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00562	0.00584	CcSEcCtD
Solifenacin—Urinary tract infection—Carmustine—lymphatic system cancer	0.00559	0.00581	CcSEcCtD
Solifenacin—Rash—Mechlorethamine—lymphatic system cancer	0.00558	0.0058	CcSEcCtD
Solifenacin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00557	0.00579	CcSEcCtD
Solifenacin—Depression—Vincristine—lymphatic system cancer	0.00547	0.00569	CcSEcCtD
Solifenacin—Feeling abnormal—Teniposide—lymphatic system cancer	0.00537	0.00559	CcSEcCtD
Solifenacin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00533	0.00554	CcSEcCtD
Solifenacin—Renal failure—Mitoxantrone—lymphatic system cancer	0.00526	0.00546	CcSEcCtD
Solifenacin—Nausea—Mechlorethamine—lymphatic system cancer	0.00525	0.00546	CcSEcCtD
Solifenacin—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.0052	0.0054	CcSEcCtD
Solifenacin—Urticaria—Teniposide—lymphatic system cancer	0.00518	0.00538	CcSEcCtD
Solifenacin—Abdominal pain—Teniposide—lymphatic system cancer	0.00515	0.00536	CcSEcCtD
Solifenacin—Hallucination—Carmustine—lymphatic system cancer	0.00514	0.00534	CcSEcCtD
Solifenacin—Oedema peripheral—Carmustine—lymphatic system cancer	0.00509	0.00529	CcSEcCtD
Solifenacin—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00507	0.00527	CcSEcCtD
Solifenacin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00504	0.00524	CcSEcCtD
Solifenacin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00498	0.00518	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00495	0.00514	CcSEcCtD
Solifenacin—Fatigue—Fludarabine—lymphatic system cancer	0.00494	0.00514	CcSEcCtD
Solifenacin—Hallucination—Vincristine—lymphatic system cancer	0.0049	0.0051	CcSEcCtD
Solifenacin—Constipation—Fludarabine—lymphatic system cancer	0.0049	0.00509	CcSEcCtD
Solifenacin—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00487	0.00506	CcSEcCtD
Solifenacin—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00484	0.00503	CcSEcCtD
Solifenacin—Urethral disorder—Vincristine—lymphatic system cancer	0.00483	0.00502	CcSEcCtD
Solifenacin—Eye disorder—Carmustine—lymphatic system cancer	0.00482	0.00501	CcSEcCtD
Solifenacin—Hypersensitivity—Teniposide—lymphatic system cancer	0.0048	0.00499	CcSEcCtD
Solifenacin—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00476	0.00495	CcSEcCtD
Solifenacin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00472	0.00491	CcSEcCtD
Solifenacin—Asthenia—Teniposide—lymphatic system cancer	0.00468	0.00486	CcSEcCtD
Solifenacin—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00465	0.00483	CcSEcCtD
Solifenacin—Pruritus—Teniposide—lymphatic system cancer	0.00461	0.0048	CcSEcCtD
Solifenacin—Cystitis—Methotrexate—lymphatic system cancer	0.0046	0.00478	CcSEcCtD
Solifenacin—Cardiac disorder—Vincristine—lymphatic system cancer	0.00457	0.00475	CcSEcCtD
Solifenacin—Mental disorder—Carmustine—lymphatic system cancer	0.00452	0.0047	CcSEcCtD
Solifenacin—Malnutrition—Carmustine—lymphatic system cancer	0.00449	0.00467	CcSEcCtD
Solifenacin—Cough—Bleomycin—lymphatic system cancer	0.00449	0.00467	CcSEcCtD
Solifenacin—Angiopathy—Vincristine—lymphatic system cancer	0.00447	0.00465	CcSEcCtD
Solifenacin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00444	0.00462	CcSEcCtD
Solifenacin—Mental disorder—Vincristine—lymphatic system cancer	0.00432	0.00449	CcSEcCtD
Solifenacin—Bladder pain—Methotrexate—lymphatic system cancer	0.00431	0.00447	CcSEcCtD
Solifenacin—Confusional state—Bleomycin—lymphatic system cancer	0.00424	0.0044	CcSEcCtD
Solifenacin—Vision blurred—Carmustine—lymphatic system cancer	0.00424	0.0044	CcSEcCtD
Solifenacin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00422	0.00439	CcSEcCtD
Solifenacin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.0042	0.00437	CcSEcCtD
Solifenacin—Infection—Bleomycin—lymphatic system cancer	0.00417	0.00434	CcSEcCtD
Solifenacin—Vomiting—Teniposide—lymphatic system cancer	0.00415	0.00431	CcSEcCtD
Solifenacin—Asthenia—Fludarabine—lymphatic system cancer	0.00411	0.00427	CcSEcCtD
Solifenacin—Rash—Teniposide—lymphatic system cancer	0.00411	0.00427	CcSEcCtD
Solifenacin—Dermatitis—Teniposide—lymphatic system cancer	0.00411	0.00427	CcSEcCtD
Solifenacin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00409	0.00425	CcSEcCtD
Solifenacin—Headache—Teniposide—lymphatic system cancer	0.00409	0.00425	CcSEcCtD
Solifenacin—Pruritus—Fludarabine—lymphatic system cancer	0.00405	0.00421	CcSEcCtD
Solifenacin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00394	0.00409	CcSEcCtD
Solifenacin—Hypertension—Carmustine—lymphatic system cancer	0.00388	0.00403	CcSEcCtD
Solifenacin—Nausea—Teniposide—lymphatic system cancer	0.00387	0.00403	CcSEcCtD
Solifenacin—Hypertension—Vincristine—lymphatic system cancer	0.0037	0.00385	CcSEcCtD
Solifenacin—Confusional state—Carmustine—lymphatic system cancer	0.0037	0.00384	CcSEcCtD
Solifenacin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00366	0.00381	CcSEcCtD
Solifenacin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00365	0.0038	CcSEcCtD
Solifenacin—Cough—Mitoxantrone—lymphatic system cancer	0.00365	0.00379	CcSEcCtD
Solifenacin—Infection—Carmustine—lymphatic system cancer	0.00364	0.00379	CcSEcCtD
Solifenacin—Vomiting—Fludarabine—lymphatic system cancer	0.00364	0.00379	CcSEcCtD
Solifenacin—Rash—Fludarabine—lymphatic system cancer	0.00361	0.00376	CcSEcCtD
Solifenacin—Dermatitis—Fludarabine—lymphatic system cancer	0.00361	0.00375	CcSEcCtD
Solifenacin—Hypertension—Mitoxantrone—lymphatic system cancer	0.00361	0.00375	CcSEcCtD
Solifenacin—Headache—Fludarabine—lymphatic system cancer	0.00359	0.00373	CcSEcCtD
Solifenacin—Tachycardia—Carmustine—lymphatic system cancer	0.00358	0.00372	CcSEcCtD
Solifenacin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.0035	0.00364	CcSEcCtD
Solifenacin—Infection—Vincristine—lymphatic system cancer	0.00348	0.00362	CcSEcCtD
Solifenacin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00346	0.0036	CcSEcCtD
Solifenacin—Confusional state—Mitoxantrone—lymphatic system cancer	0.00344	0.00357	CcSEcCtD
Solifenacin—Nervous system disorder—Vincristine—lymphatic system cancer	0.00343	0.00357	CcSEcCtD
Solifenacin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00341	0.00354	CcSEcCtD
Solifenacin—Nausea—Fludarabine—lymphatic system cancer	0.0034	0.00354	CcSEcCtD
Solifenacin—Infection—Mitoxantrone—lymphatic system cancer	0.00339	0.00352	CcSEcCtD
Solifenacin—Urticaria—Bleomycin—lymphatic system cancer	0.00334	0.00347	CcSEcCtD
Solifenacin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00333	0.00346	CcSEcCtD
Solifenacin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00331	0.00344	CcSEcCtD
Solifenacin—Somnolence—Carmustine—lymphatic system cancer	0.00326	0.00339	CcSEcCtD
Solifenacin—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00319	0.00332	CcSEcCtD
Solifenacin—Decreased appetite—Carmustine—lymphatic system cancer	0.00319	0.00331	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00317	0.00329	CcSEcCtD
Solifenacin—Constipation—Carmustine—lymphatic system cancer	0.00314	0.00326	CcSEcCtD
Solifenacin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0031	0.00322	CcSEcCtD
Solifenacin—Decreased appetite—Vincristine—lymphatic system cancer	0.00304	0.00316	CcSEcCtD
Solifenacin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00303	0.00315	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00302	0.00314	CcSEcCtD
Solifenacin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00302	0.00314	CcSEcCtD
Solifenacin—Fatigue—Vincristine—lymphatic system cancer	0.00302	0.00314	CcSEcCtD
Solifenacin—Asthenia—Bleomycin—lymphatic system cancer	0.00301	0.00313	CcSEcCtD
Solifenacin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.003	0.00312	CcSEcCtD
Solifenacin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.003	0.00312	CcSEcCtD
Solifenacin—Constipation—Vincristine—lymphatic system cancer	0.00299	0.00311	CcSEcCtD
Solifenacin—Pruritus—Bleomycin—lymphatic system cancer	0.00297	0.00309	CcSEcCtD
Solifenacin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00296	0.00308	CcSEcCtD
Solifenacin—Fatigue—Mitoxantrone—lymphatic system cancer	0.00294	0.00306	CcSEcCtD
Solifenacin—Constipation—Mitoxantrone—lymphatic system cancer	0.00292	0.00303	CcSEcCtD
Solifenacin—Abdominal pain—Carmustine—lymphatic system cancer	0.0029	0.00301	CcSEcCtD
Solifenacin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00286	0.00298	CcSEcCtD
Solifenacin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00281	0.00292	CcSEcCtD
Solifenacin—Dysuria—Methotrexate—lymphatic system cancer	0.00279	0.0029	CcSEcCtD
Solifenacin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00279	0.0029	CcSEcCtD
Solifenacin—Abdominal pain—Vincristine—lymphatic system cancer	0.00277	0.00288	CcSEcCtD
Solifenacin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00271	0.00282	CcSEcCtD
Solifenacin—Hypersensitivity—Carmustine—lymphatic system cancer	0.0027	0.00281	CcSEcCtD
Solifenacin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0027	0.0028	CcSEcCtD
Solifenacin—Vomiting—Bleomycin—lymphatic system cancer	0.00267	0.00278	CcSEcCtD
Solifenacin—Infestation NOS—Methotrexate—lymphatic system cancer	0.00266	0.00277	CcSEcCtD
Solifenacin—Infestation—Methotrexate—lymphatic system cancer	0.00266	0.00277	CcSEcCtD
Solifenacin—Depression—Methotrexate—lymphatic system cancer	0.00266	0.00276	CcSEcCtD
Solifenacin—Rash—Bleomycin—lymphatic system cancer	0.00265	0.00275	CcSEcCtD
Solifenacin—Dermatitis—Bleomycin—lymphatic system cancer	0.00265	0.00275	CcSEcCtD
Solifenacin—Asthenia—Carmustine—lymphatic system cancer	0.00263	0.00274	CcSEcCtD
Solifenacin—Renal failure—Methotrexate—lymphatic system cancer	0.00262	0.00272	CcSEcCtD
Solifenacin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00258	0.00268	CcSEcCtD
Solifenacin—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00252	0.00262	CcSEcCtD
Solifenacin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00251	0.00261	CcSEcCtD
Solifenacin—Asthenia—Vincristine—lymphatic system cancer	0.00251	0.00261	CcSEcCtD
Solifenacin—Nausea—Bleomycin—lymphatic system cancer	0.0025	0.00259	CcSEcCtD
Solifenacin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00245	0.00254	CcSEcCtD
Solifenacin—Dizziness—Carmustine—lymphatic system cancer	0.00243	0.00252	CcSEcCtD
Solifenacin—Pharyngitis—Methotrexate—lymphatic system cancer	0.00237	0.00247	CcSEcCtD
Solifenacin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00236	0.00245	CcSEcCtD
Solifenacin—Urethral disorder—Methotrexate—lymphatic system cancer	0.00234	0.00244	CcSEcCtD
Solifenacin—Vomiting—Carmustine—lymphatic system cancer	0.00233	0.00242	CcSEcCtD
Solifenacin—Dizziness—Vincristine—lymphatic system cancer	0.00232	0.00241	CcSEcCtD
Solifenacin—Rash—Carmustine—lymphatic system cancer	0.00231	0.0024	CcSEcCtD
Solifenacin—Dermatitis—Carmustine—lymphatic system cancer	0.00231	0.0024	CcSEcCtD
Solifenacin—Headache—Carmustine—lymphatic system cancer	0.0023	0.00239	CcSEcCtD
Solifenacin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00226	0.00235	CcSEcCtD
Solifenacin—Eye disorder—Methotrexate—lymphatic system cancer	0.00223	0.00232	CcSEcCtD
Solifenacin—Vomiting—Vincristine—lymphatic system cancer	0.00223	0.00231	CcSEcCtD
Solifenacin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00222	0.00231	CcSEcCtD
Solifenacin—Rash—Vincristine—lymphatic system cancer	0.00221	0.00229	CcSEcCtD
Solifenacin—Dermatitis—Vincristine—lymphatic system cancer	0.00221	0.00229	CcSEcCtD
Solifenacin—Headache—Vincristine—lymphatic system cancer	0.00219	0.00228	CcSEcCtD
Solifenacin—Nausea—Carmustine—lymphatic system cancer	0.00218	0.00226	CcSEcCtD
Solifenacin—Angiopathy—Methotrexate—lymphatic system cancer	0.00217	0.00226	CcSEcCtD
Solifenacin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00217	0.00225	CcSEcCtD
Solifenacin—Immune system disorder—Methotrexate—lymphatic system cancer	0.00216	0.00224	CcSEcCtD
Solifenacin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00216	0.00224	CcSEcCtD
Solifenacin—Rash—Mitoxantrone—lymphatic system cancer	0.00215	0.00223	CcSEcCtD
Solifenacin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00215	0.00223	CcSEcCtD
Solifenacin—Headache—Mitoxantrone—lymphatic system cancer	0.00214	0.00222	CcSEcCtD
Solifenacin—Mental disorder—Methotrexate—lymphatic system cancer	0.0021	0.00218	CcSEcCtD
Solifenacin—Malnutrition—Methotrexate—lymphatic system cancer	0.00208	0.00216	CcSEcCtD
Solifenacin—Nausea—Vincristine—lymphatic system cancer	0.00208	0.00216	CcSEcCtD
Solifenacin—Dysgeusia—Methotrexate—lymphatic system cancer	0.00204	0.00212	CcSEcCtD
Solifenacin—Nausea—Mitoxantrone—lymphatic system cancer	0.00203	0.00211	CcSEcCtD
Solifenacin—Vision blurred—Methotrexate—lymphatic system cancer	0.00196	0.00204	CcSEcCtD
Solifenacin—Cough—Methotrexate—lymphatic system cancer	0.00182	0.00189	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00176	0.00183	CcSEcCtD
Solifenacin—Confusional state—Methotrexate—lymphatic system cancer	0.00171	0.00178	CcSEcCtD
Solifenacin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.0017	0.00177	CcSEcCtD
Solifenacin—Infection—Methotrexate—lymphatic system cancer	0.00169	0.00175	CcSEcCtD
Solifenacin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00167	0.00173	CcSEcCtD
Solifenacin—Skin disorder—Methotrexate—lymphatic system cancer	0.00165	0.00172	CcSEcCtD
Solifenacin—Somnolence—Methotrexate—lymphatic system cancer	0.00151	0.00157	CcSEcCtD
Solifenacin—Dyspepsia—Methotrexate—lymphatic system cancer	0.0015	0.00155	CcSEcCtD
Solifenacin—Decreased appetite—Methotrexate—lymphatic system cancer	0.00148	0.00154	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00147	0.00152	CcSEcCtD
Solifenacin—Fatigue—Methotrexate—lymphatic system cancer	0.00146	0.00152	CcSEcCtD
Solifenacin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.0014	0.00146	CcSEcCtD
Solifenacin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00139	0.00144	CcSEcCtD
Solifenacin—Urticaria—Methotrexate—lymphatic system cancer	0.00135	0.0014	CcSEcCtD
Solifenacin—Abdominal pain—Methotrexate—lymphatic system cancer	0.00134	0.0014	CcSEcCtD
Solifenacin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00125	0.0013	CcSEcCtD
Solifenacin—Asthenia—Methotrexate—lymphatic system cancer	0.00122	0.00127	CcSEcCtD
Solifenacin—Pruritus—Methotrexate—lymphatic system cancer	0.0012	0.00125	CcSEcCtD
Solifenacin—Dizziness—Methotrexate—lymphatic system cancer	0.00112	0.00117	CcSEcCtD
Solifenacin—Vomiting—Methotrexate—lymphatic system cancer	0.00108	0.00112	CcSEcCtD
Solifenacin—Rash—Methotrexate—lymphatic system cancer	0.00107	0.00111	CcSEcCtD
Solifenacin—Dermatitis—Methotrexate—lymphatic system cancer	0.00107	0.00111	CcSEcCtD
Solifenacin—Headache—Methotrexate—lymphatic system cancer	0.00106	0.00111	CcSEcCtD
Solifenacin—Nausea—Methotrexate—lymphatic system cancer	0.00101	0.00105	CcSEcCtD
